Esperion Therapeutics Stock Analysis

ESPR Stock  USD 1.69  0.05  2.87%   
Esperion Therapeutics is undervalued with Real Value of 3.0 and Target Price of 7.13. The main objective of Esperion Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Esperion Therapeutics is worth, separate from its market price. There are two main types of Esperion Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Esperion Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Esperion Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Esperion Stock trading window is adjusted to America/New York timezone.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Esperion Stock Analysis Notes

About 66.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.28. Esperion Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 11th of June 2013. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Esperion Theraptc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 218 people. To learn more about Esperion Therapeutics call Sheldon Koenig at 734 887 3903 or check out https://www.esperion.com.

Esperion Therapeutics Investment Alerts

Esperion Therapeutics generated a negative expected return over the last 90 days
Esperion Therapeutics may become a speculative penny stock
Esperion Therapeutics has high historical volatility and very poor performance
Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 217.48 M.
Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

Esperion Therapeutics Upcoming and Recent Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Esperion Largest EPS Surprises

Earnings surprises can significantly impact Esperion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-05
2024-09-30-0.18-0.150.0316 
2025-02-25
2024-12-31-0.1575-0.10130.056235 
2023-11-07
2023-09-30-0.43-0.370.0613 
View All Earnings Estimates

Esperion Therapeutics Thematic Classifications

In addition to having Esperion Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Drugs Idea
Drugs
Drug manufacturing and delivery

Esperion Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Nuveen Asset Management, Llc2024-12-31
3.1 M
Indaba Capital Management, Llc2024-12-31
M
Goldman Sachs Group Inc2024-12-31
2.8 M
Jpmorgan Chase & Co2024-12-31
2.5 M
Rhenman Partners Asset Management Ab2024-12-31
1.9 M
Citadel Advisors Llc2024-12-31
1.8 M
Bank Of America Corp2024-12-31
1.6 M
Northern Trust Corp2024-12-31
1.5 M
Woodline Partners Lp2024-12-31
1.5 M
Wasatch Advisors Lp2024-12-31
24.5 M
Blackrock Inc2024-12-31
14.2 M
Note, although Esperion Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Esperion Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 344.26 M.

Esperion Profitablity

The company has Profit Margin (PM) of (0.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.06.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed 0.56  0.59 
Return On Assets(0.15)(0.16)
Return On Equity 0.13  0.14 

Management Efficiency

Esperion Therapeutics has return on total asset (ROA) of 0.1237 % which means that it generated a profit of $0.1237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics' management efficiency ratios could be used to measure how well Esperion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Esperion Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 03/25/2025, Return On Equity is likely to grow to 0.14, while Return On Tangible Assets are likely to drop (0.16). As of 03/25/2025, Other Current Assets is likely to grow to about 19.5 M, while Total Assets are likely to drop slightly above 192.8 M.
Last ReportedProjected for Next Year
Book Value Per Share(2.08)(1.97)
Tangible Book Value Per Share(2.08)(1.97)
Enterprise Value Over EBITDA 74.60  78.33 
Price Book Value Ratio(1.06)(1.01)
Enterprise Value Multiple 74.60  78.33 
Price Fair Value(1.06)(1.01)
Enterprise Value564.6 M538.4 M
Effective leadership at Esperion Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin
(0.06)
Profit Margin
(0.16)
Beta
1.042
Return On Assets
0.1237
Return On Equity
(2.61)

Technical Drivers

As of the 25th of March, Esperion Therapeutics shows the Standard Deviation of 3.86, mean deviation of 2.87, and Variance of 14.92. Esperion Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Esperion Therapeutics information ratio and kurtosis to decide if Esperion Therapeutics is priced favorably, providing market reflects its regular price of 1.69 per share. Please also check Esperion Therapeutics jensen alpha, which is currently at (0.39) to verify the company can sustain itself at a future point.

Esperion Therapeutics Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Esperion Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Esperion Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Esperion Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Esperion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Sheldon Koenig six days ago
Disposition of 13047 shares by Sheldon Koenig of Esperion Therapeutics at 1.504 subject to Rule 16b-3
 
Benjamin Looker over a week ago
Acquisition by Benjamin Looker of 201000 shares of Esperion Therapeutics at 1.5 subject to Rule 16b-3
 
Halladay Benjamin over a month ago
Disposition of tradable shares by Halladay Benjamin of Esperion Therapeutics at 1.86 subject to Rule 16b-3
 
Warren Eric over two months ago
Disposition of 123 shares by Warren Eric of Esperion Therapeutics at 2.26 subject to Rule 16b-3
 
Benjamin Looker over three months ago
Acquisition by Benjamin Looker of 20500 shares of Esperion Therapeutics subject to Rule 16b-3
 
Sheldon Koenig over three months ago
Disposition of 12447 shares by Sheldon Koenig of Esperion Therapeutics at 2.466 subject to Rule 16b-3
 
Warren Eric over three months ago
Disposition of 197 shares by Warren Eric of Esperion Therapeutics at 2.165 subject to Rule 16b-3
 
Warren Eric over six months ago
Disposition of 2608 shares by Warren Eric of Esperion Therapeutics at 1.783 subject to Rule 16b-3
 
Shepard Jay over six months ago
Acquisition by Shepard Jay of 23000 shares of Esperion Therapeutics subject to Rule 16b-3
 
Warren Eric over six months ago
Disposition of 2540 shares by Warren Eric of Esperion Therapeutics at 2.856 subject to Rule 16b-3
 
Foody Joanne M. over six months ago
Disposition of 01 shares by Foody Joanne M. of Esperion Therapeutics at 6.55 subject to Rule 16b-3
 
Warren Eric over six months ago
Disposition of 192 shares by Warren Eric of Esperion Therapeutics at 2.483 subject to Rule 16b-3

Esperion Therapeutics Outstanding Bonds

Esperion Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Esperion Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Esperion bonds can be classified according to their maturity, which is the date when Esperion Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Esperion Therapeutics Predictive Daily Indicators

Esperion Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Esperion Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Esperion Therapeutics Forecast Models

Esperion Therapeutics' time-series forecasting models are one of many Esperion Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Esperion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Esperion Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Esperion Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Esperion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Esperion Therapeutics. By using and applying Esperion Stock analysis, traders can create a robust methodology for identifying Esperion entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.16)(0.16)
Operating Profit Margin 0.16  0.17 
Net Loss(0.16)(0.16)
Gross Profit Margin 0.57  0.52 

Current Esperion Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Esperion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Esperion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.13Buy9Odds
Esperion Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Esperion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Esperion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Esperion Therapeutics, talking to its executives and customers, or listening to Esperion conference calls.
Esperion Analyst Advice Details

Esperion Stock Analysis Indicators

Esperion Therapeutics stock analysis indicators help investors evaluate how Esperion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Esperion Therapeutics shares will generate the highest return on investment. By understating and applying Esperion Therapeutics stock analysis, traders can identify Esperion Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow82.2 M
Long Term Debt237.7 M
Common Stock Shares Outstanding187.2 M
Total Stockholder Equity-388.7 M
Property Plant And Equipment Net5.8 M
Cash And Short Term Investments144.8 M
Cash144.8 M
Accounts Payable51.6 M
Net Debt152.8 M
50 Day M A1.8364
Total Current Liabilities246.2 M
Other Operating Expenses277.9 M
Non Current Assets Total5.8 M
Forward Price Earnings1.345
Stock Based Compensation12 M

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.